GeneDx Holdings EBIT Margin 2020-2025 | WGS
Current and historical EBIT (Earnings Before Interest & Taxes) margin for GeneDx Holdings (WGS) over the last 10 years. The current EBIT profit margin for GeneDx Holdings as of March 31, 2025 is .
| GeneDx Holdings EBIT Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBIT | EBIT Margin |
| 2025-03-31 | $0.33B | $-0.02B | -4.53% |
| 2024-12-31 | $0.31B | $-0.02B | -7.84% |
| 2024-09-30 | $0.27B | $-0.06B | -22.10% |
| 2024-06-30 | $0.24B | $-0.09B | -38.68% |
| 2024-03-31 | $0.22B | $-0.14B | -61.09% |
| 2023-12-31 | $0.20B | $-0.18B | -89.60% |
| 2023-09-30 | $0.21B | $-0.48B | -233.01% |
| 2023-06-30 | $0.24B | $-0.53B | -223.73% |
| 2023-03-31 | $0.22B | $-0.64B | -286.55% |
| 2022-12-31 | $0.23B | $-0.67B | -285.47% |
| 2022-09-30 | $0.23B | $-0.46B | -198.70% |
| 2022-06-30 | $0.19B | $-0.46B | -238.74% |
| 2022-03-31 | $0.20B | $-0.34B | -167.33% |
| 2021-12-31 | $0.21B | $-0.45B | -210.38% |
| 2021-06-30 | $0.15B | $-0.30B | -198.67% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $1.887B | $0.305B |
| GeneDx Holdings Corp. is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by rare disease data sets. GeneDx Holdings Corp., formerly known as Sema4 Holdings Corp., is based in STAMFORD, Conn. | |||